Logo Image
|Articles|January 5, 2022

BP Elements

  • BioPharm International's BP Elements, January 2022
  • Volume 1
  • Issue 1

New High Fidelity CRISPR Cas9 Protein Reduces Off-Target Effects

Thermo Fisher Scientific’s Invitrogen TrueCut HiFi Cas9 Protein offers the advantage of significantly minimizing off-target events while aiming to retain maximum on-target editing efficiency.

Thermo Fisher Scientific’s new Invitrogen TrueCut Hifi Cas9 Protein is designed for research applications that require highly precise genome editing, such as the engineering of chimeric antigen receptor (CAR)-T cells and the creation of cellular models for disease discovery. Launched in late November 2021, the new protein significantly minimizes off-target events while retaining maximum on-target editing efficiency.

The Invitrogen TrueCut HiFi Cas9 Protein complements Thermo Fisher’s existing portfolio of clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing solutions by minimizing edits in unintended locations, which the company stated in a Nov. 30, 2021 press release are very disruptive in translational research, drug screening, and drug modeling. According to Thermo Fisher, the protein demonstrates near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs). The company also stated that it has demonstrated improved off-target profiles relative to other products on the market in the release.

"Our pharma and biotech customers are looking for highly precise, accurate solutions to harness the power of CRISPR genome editing," said Brandon Pence, vice-president and general manager of cell biology at Thermo Fisher Scientific, in the press release. "Nothing is more disappointing than to find out months after an edit that the biological response you are measuring was due to an unintended off-target edit. The new Invitrogen TrueCut HiFi Cas9 Protein offers researchers the confidence that their edits took place where they intended, not somewhere else in the genome."

Source: Thermo Fisher Scientific

Articles in this issue

almost 5 years ago

Elements that are Key for Successful Assay Transfer

almost 5 years ago

COVID Pandemic Prompts Renewed Interest in Biotech Startups

almost 5 years ago

Bio-Rad Introduces SARS-CoV-2 Variant Neutralization Antibody Assays

almost 5 years ago

FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

almost 5 years ago

Insightful Science Completes Acquisition of Protein Metrics

almost 5 years ago

OpenEye Scientific and Specifica Partner to Launch Orion Antibody Discovery Suite

almost 5 years ago

Amgen Extends Collaboration with Syngene International

almost 5 years ago

Genezen Starts Up Operations at Lenti- and Retroviral Vector Process Development Lab

almost 5 years ago

GSK and University of Oxford Partner on Disease Research to Advance Drug Discovery and Development

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more